Compass Therapeutics

Compare

396 Followers

CMPX Stock Chart & Stats

$3.97

$0.48(33.57%)

At close: Jan 08 4:00 PM EST

$3.97

$0.48(33.57%)

Day’s Range― - ―

52-Week Range$1.27 - $4.86

Previous CloseN/A

Volume16.21M

Average Volume (3M)1.86M

Market Cap

$681.14M

Enterprise Value$268.49M

Total Cash (Recent Filing)$100.95M

Total Debt (Recent Filing)$9.90M

Price to Earnings (P/E)―

Beta2.03

Next Earnings

Nov 06, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding171,572,500

10 Day Avg. Volume1,898,944

30 Day Avg. Volume1,863,109

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.39

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-731.58

Enterprise Value/Ebitda-4.03

Forecast

1Y Price Target

$12.29

Price Target Upside209.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommendation for Compass Therapeutics is OUTPERFORM based on its promising pipeline and market opportunities.

Clinical Trial SuccessCompass Therapeutics announced positive topline results on the primary efficacy endpoint for COMPANION-002, the company's ongoing Phase 2/3 randomized study of tovecimig in combination with paclitaxel in patients with advanced BTC.

Market PotentialSEER data suggests approximately 23,000 annual US patients, a figure supported by AZN and independent parties, indicating a larger than expected market size for BTC.

Bears Say

Compass Therapeutics News

Compass Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 23-27 hosted by Piper Sandler. Published first on TheFly...

7d ago

CMPX

Compass Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target Published first...

22d ago

CMPX

Compass Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 8 hosted by Piper Sandler. Published first on TheFly...

27d ago

CMPX

Compass Therapeutics’ Phase 1 Study of CTX-8371: A Potential Game-Changer in Cancer Treatment

Compass Therapeutics, Inc. (($CMPX)) announced an update on their ongoing clinical study. Compass Therapeutics, Inc. is conducting a...

21h ago

CMPX

Promising Outlook for Compass Therapeutics: Buy Rating Backed by COMPANION-002 Trial Success and Market Potential

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics and keeping the price target...

11d ago

CMPX

Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment

Compass Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from...

16d ago

CMPX

Positive Outlook for Compass Therapeutics: Buy Rating Backed by Promising Pipeline and Market Potential

Compass Therapeutics (CMPX) has received a new Buy rating, initiated by LifeSci Capital analyst, Charles Zhu. Charles Zhu...

22d ago

CMPX

Compass Therapeutics Announces Public Offering to Raise $112.5M

An update from Compass Therapeutics ( ($CMPX) ) is now available. On August 12, 2025, Compass Therapeutics announced...

3M ago

CMPX

Compass Therapeutics 33.3M share Spot Secondary priced at $3.00

Jefferies, Piper Sandler and Guggenheim acted as joint book running managers for the offering. Published first on TheFly...

3M ago

CMPX

Compass Therapeutics announces common stock offering, no amount given

Compass Therapeutics (CMPX) announced the launch of an underwritten public offering of its common stock and, in lieu...

3M ago

CMPX

Compass Therapeutics price target raised to $12 from $10 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Compass Therapeutics (CMPX) to $12 from $10 and...

3M ago

CMPX

Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions

Compass Therapeutics, Inc. (CMPX) has disclosed a new risk, in the Economy & Political Environment category. Compass Therapeutics,...

3M ago

CMPX

Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress

Compass Therapeutics, Inc. ( ($CMPX) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

CMPX

Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, with...

3M ago

CMPX

CMPX FAQ

What was Compass Therapeutics’s price range in the past 12 months?

Compass Therapeutics lowest stock price was $1.27 and its highest was $4.86 in the past 12 months.

What is Compass Therapeutics’s market cap?

Compass Therapeutics’s market cap is $681.14M.

When is Compass Therapeutics’s upcoming earnings report date?

Compass Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 9 days.

How were Compass Therapeutics’s earnings last quarter?

Compass Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.016.

Is Compass Therapeutics overvalued?

According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compass Therapeutics pay dividends?

Compass Therapeutics does not currently pay dividends.

What is Compass Therapeutics’s EPS estimate?

Compass Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Compass Therapeutics have?

Compass Therapeutics has 171,572,500 shares outstanding.

What happened to Compass Therapeutics’s price movement after its last earnings report?

Compass Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 23.704%.

Which hedge fund is a major shareholder of Compass Therapeutics?

Currently, no hedge funds are holding shares in CMPX

Compass Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.84%

Trailing 12-Months

Asset Growth

-25.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compass Therapeutics

Compass Therapeutics (CMPX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody therapeutics. The company operates in the biopharmaceutical sector, concentrating on innovative treatments that target complex diseases such as cancer and autoimmune disorders. Compass Therapeutics leverages its proprietary StitchMabsTM technology, which enables the development of bispecific and multispecific antibody therapeutics aimed at enhancing immune system response and improving patient outcomes.

Compass Therapeutics (CMPX) Earnings & Revenues

Historic Earnings Reports

CMPX Earnings Call

Q2 2025

0:00 / 0:00

CMPX Stock 12 Month Forecast

Average Price Target

$12.29

▲(209.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,4.947692307692307,6.535384615384615,8.123076923076923,9.71076923076923,11.298461538461538,12.886153846153846,14.473846153846154,16.06153846153846,17.64923076923077,19.236923076923077,20.824615384615385,22.412307692307692,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,4.046923076923076,4.733846153846153,5.42076923076923,6.107692307692307,6.794615384615384,7.481538461538461,8.168461538461537,8.855384615384615,9.542307692307691,10.22923076923077,10.916153846153845,11.603076923076921,{"y":12.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.6399999999999997,3.92,4.2,4.48,4.76,5.04,5.32,5.6,5.880000000000001,6.16,6.4399999999999995,6.720000000000001,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >